Innovation in Women's Health & Prostate Cancer

J.P. Morgan Healthcare Conference
January 2020

MYOVANT SCIENCES

Forward-Looking Statements

This presentation contains forward-looking statements, including without limitation, statements related to: Myovant's focus on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases; Myovant's ability to advance the clinical development of relugolix through the LIBERTY, SPIRIT and HERO clinical trials and MVT-602 through its clinical trials; the timing and success of Myovant's regulatory filings and potential approvals; Myovant's business strategies, financial condition and trends, competitive position, potential growth opportunities, the effects of competition and expectations or probabilities for success. Forward-looking statements can be identified by "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "likely," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "should," "to be," "will," "would," or the negative or plural of these words or other similar expressions or variations, although not all forward-looking statements contain these identifying words. Myovant cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors known and unknown that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, risks relating to those discussed in the section titled "Risk Factors" set forth in Part I, Item 1A of Myovant's Annual Report on Form 10-K filed with the United States Securities and Exchange Commission, or the SEC, on May 24, 2019, and other filings that Myovant makes with the SEC from time to time. These risks are not exhaustive. New risk factors emerge from time to time and it is not possible for its management to predict all risk factors, nor can Myovant assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. Except as required by law, Myovant undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

Improve the lives of millions of women and men, many impacted by diseases during their most productive years of life.

A Unique Investment Opportunity

2019

Positive Phase 3 Data:

- **Uterine Fibroids**
- **Prostate Cancer**

2020

Endometriosis:

- **Phase 3 Data**

Uterine Fibroids:

- **1-Year Data**
- **NDA Submission**
- **MAA Submission**

Prostate Cancer:

- **NDA Submission**
- **Castration Resistance-Free Survival Data**

~$400M

Cash and committed funding

RIGHTS

Wholly-owned U.S. and EU rights for all indications

MYOVANT SCIENCES

Myovant's Late-Stage Pipeline



MAA = Marketing Authorisation Application for European Medicines Agency

Relugolix Combination Therapy = relugolix 40 mg + estradiol 1.0 mg and norethindrone acetate 0.5 mg

MYOVANT SCIENCES

GnRH Pathway

Shared Across Women's Health and Prostate Cancer



Definition: Follicle-Stimulating Hormone (FSH); Luteinizing Hormone (LH)

MYOVANT SCIENCES

Relugolix Mechanism of Action



Definition: Follicle-Stimulating Hormone (FSH); Luteinizing Hormone (LH)

MYOVANT SCIENCES

One Pill, Once A Day

Two Distinct Therapeutic Candidates

WOMEN'S HEALTH

Relugolix 40 mg
+ estradiol 1.0 mg
+ norethindrone acetate 0.5 mg

RELUGOLIX COMBINATION TABLET

Designed for the treatment of women with symptomatic uterine fibroids or endometriosis as an alternative to surgery or other invasive procedures.

PROSTATE CANCER

Relugolix 120 mg
(following single 360 mg loading dose)

RELUGOLIX MONOTHERAPY TABLET

Designed with the potential to be the first and only oral androgen deprivation therapy for men with advanced prostate cancer.

***Relugolix is an investigational drug that has not been FDA approved for use**

MYOVANT SCIENCES

Relugolix for **Women's Health**

Millions of Women
In Need of Better Medicines for Uterine Fibroids



Stewart. NEJM. 2015; Stewart. Lancet. 2001
Majoribanks et al. Cochrane Database Syst. Rev. 2006. Cardozo et al. Am J Obstet Gynecol. 2012;
Wright et al. Obstet Gynecol. 2013; Cohen et al. Obstet Gynecol. 2017.

Uterine Fibroids: A Common, Debilitating Disease



EFFECTS

Heavy Bleeding

Anemia

Pelvic Pain

Urinary Symptoms

Pregnancy Complications

Stewart. *NEJM*. 2015; Stewart. *Lancet*. 2001.

MYOVANT SCIENCES

Millions of Women
In Need of Better Medicines for Endometriosis

Bulletti et al. *J Assist Reprod Genet*. 2010; Quaas et al. *Fertil Steril*. 2015; Simoens et al. *Human Reproduction*. 2012; Wright et al. *Obstet Gynecol*. 2013; Cohen et al. *Obstet Gynecol*. 2017.

Endometriosis: A Common, Debilitating Disease



Bulun. 2019. *NEJM.* 2009; Vercillini et al. *Nature Reviews Endocrinology*. 2014.

MYOVANT SCIENCES

Despite the significant burden of uterine fibroids and endometriosis, women do not have the options they deserve and need.

MYOVANT SCIENCES

A Clearly Defined Gap in Treatment in Uterine Fibroids and Endometriosis

HIGHER ESTROGEN

Contraceptives

GnRH Antagonist Monotherapy
Low Dose

TARGET

LOWER ESTROGEN

GnRH Antagonists Monotherapy
High Dose

GnRH Agonists

INCOMPLETE SYMPTOM RELIEF

- Blood loss
- Pain
- Anemia

TREATMENT-INDUCED SIDE EFFECTS

- Bone loss
- Hot flashes

MYOVANT SCIENCES

Relugolix Combination Vision

Intentionally Designed to Fill Treatment Gap

HIGHER ESTROGEN

Contraceptives

GnRH Antagonist Monotherapy Low Dose

INCOMPLETE SYMPTOM RELIEF

- Blood loss
- Pain
- Anemia

TARGET

RELUGOLIX COMBINATION TABLET VISION

- **Reduction in blood loss & pain**
- **Well-tolerated with bone health maintained**
- **One pill, once a day**

LOWER ESTROGEN

GnRH Antagonist Monotherapy High Dose

GnRH Agonists

TREATMENT-INDUCED SIDE EFFECTS

- Bone loss
- Hot flashes

***Relugolix is an investigational drug that has not been FDA approved for use; these are aspirational statements**

MYOVANT SCIENCES

Relugolix Combination Tablet Vision: One Dose, Two Diseases

	RELUGOLIX COMBINATION TABLET*	OTHER
ENDOMETRIOSIS	One pill, once a day  8 mm	QD: 150 mg OR BID: 200 mg + 200 mg OR BID*: 200 mg + 200 mg E2/N
UTERINE FIBROIDS		BID*: 300 mg + 300 mg OR BID*: 300 mg + 300 mg E2/N

Pills and tablets to scale (except 300 mg; size is unknown)
E2/N = estradiol and norethindrone acetate

*In late-stage clinical development

***Relugolix is an investigational drug that has not been FDA approved for use**

MYOVANT SCIENCES

LIBERTY Development Program: Long-Term Data



Relugolix Combination Therapy = relugolix 40 mg + estradiol 1.0 mg and norethindrone acetate 0.5 mg

MYOVANT SCIENCES

MYOVANT SCIENCES

Relugolix Combination: **LIBERTY Clinical Data Insights**

1. **84.3% Reduction in Menstrual Blood Loss**
2. **Reduction in Pain**
3. **Bone Mineral Density Comparable to Placebo**
4. **Well-Tolerated with Adverse Event Rates Comparable to Placebo**
5. **One Dose, Once a Day**

*Relugolix is an investigational drug that has not been FDA approved for use

Reduction in Menstrual Blood Loss Volume with Relugolix Combination Therapy

Placebo Relugolix Combination Therapy

AT WEEK 24



OVER TREATMENT PERIOD



Data Presented at American Society for Reproductive Medicine (ASRM), October, 2019.

†A patient with MBL volume of 2710.3 mL at Week 4 was excluded from the analysis.
L1 = LIBERTY 1; L2 = LIBERTY 2

Relugolix Combination Therapy = relugolix 40 mg + estradiol 1.0 mg and norethindrone acetate 0.5 mg

MYOVANT SCIENCES

Bone Health Maintained Across LIBERTY Studies (Lumbar Spine)



Relugolix Combination Therapy = relugolix 40 mg + estradiol 1.0 mg and norethindrone acetate 0.5 mg

Bone Mineral Density Distribution Comparable to Placebo in LIBERTY

Distribution of Change in Bone Mineral Density at Week 24 (Lumbar Spine)



Relugolix Combination Therapy = relugolix 40 mg + estradiol 1.0 mg and norethindrone acetate 0.5 mg

Endometriosis Phase 3 Results in Q1 and Q2 2020

CO-PRIMARY ENDPOINTS

Reduction in dysmenorrhea (painful periods) and non-menstrual pelvic pain as assessed using the Symptoms of Endometriosis Scale (a daily questionnaire for the assessment of endometriosis-associated pain) scored using the Numerical Rating Scale



Relugolix Combination Therapy = relugolix 40 mg + estradiol 1.0 mg and norethindrone acetate 0.5 mg

Relugolix for **Advanced Prostate Cancer**

The First and Only Oral GnRH Receptor Antagonist in Development for Prostate Cancer

Prostate Cancer
the 2nd Most Common Cancer Affecting Men

Androgen Deprivation Therapy (ADT) is the Foundational Treatment



National Cancer Institute; PharmaPoint Prostate Cancer 2017;
Litwin et al. *JAMA*, 2017; Sartor et al. NEJM, 2018. Datamonitor Prostate Cancer Forecast 2018. SEER 21 Database;
American College of Surgeons National Cancer Database; Albertsen et al. *Eur Urol.* 2014.

Relugolix Has Potential to Benefit Broad Spectrum of Men with Advanced Prostate Cancer



SEER 21 Database; American College of Surgeons National Cancer Database; Clinton. *Expert Opinion on Pharmacotherapy*, 2017.

***Relugolix is an investigational drug that has not been FDA approved for use; these are aspirational statements**

MYOVANT SCIENCES

HERO: Phase 3 Study Design in Advanced Prostate Cancer



☑ **Positive Phase 3 Data**

Data Available in

Q3 2020

MYOVANT SCIENCES

MYOVANT SCIENCES

The Relugolix Difference: **HERO Clinical Data Insights**

1. **Testosterone Suppression Without Clinical Flare**
2. **Testosterone Recovery Within 90 Days**
3. **50% Fewer Major Adverse Cardiovascular Events as Compared to Leuprolide**
4. **One Pill, Once A Day**

*Relugolix is an investigational drug that has not been FDA approved for use

Achieved U.S. Primary Endpoint



96.7% of men responded to treatment

Sustained testosterone suppression to castrate levels (< 50 ng/dl) with lower bound of 95% CI > 90%

CI = Confidence Interval

Relugolix Achieved Faster Onset & Recovery than Leuprolide



MYOVANT SCIENCES

Launch Readiness

- Hiring of Commercial and Medical Affairs Teams
- Advisory Boards and KOL Engagement
- Presentations and Publications
- Brand Strategies and Tactics
- Building Commercial Operations and Medical Affairs Infrastructure

MYOVANT SCIENCES

Focused and Efficient Field Team

WOMEN'S HEALTH

Millions of women with uterine fibroids and endometriosis are treated primarily by **~36K OB/GYNs in the U.S.**

PROSTATE CANCER

Men with prostate cancer are primarily treated by **~18K Urologists and Oncologists in the U.S.**

Rayburn, *The American College of Obstetricians and Gynecologists*, 2017; American Urological Association; Kirkwood et al. *J Oncol Pract*. 2013.

***Relugolix is an investigational drug that has not been FDA approved for use**

MYOVANT SCIENCES

A Unique Investment Opportunity

2019

Positive Phase 3 Data:

- **Uterine Fibroids**
- **Prostate Cancer**

2020

Endometriosis:

- **Phase 3 Data**

Uterine Fibroids:

- **1-Year Data**
- **NDA Submission**
- **MAA Submission**

Prostate Cancer:

- **NDA Submission**
- **Castration Resistance-Free Survival Data**

~$400M

Cash and committed funding

RIGHTS

Wholly-owned U.S. and EU rights for all indications

MYOVANT SCIENCES

Thank You!

Contact Email:
investors@myovant.com

MYOVANT SCIENCES